• 10x Genomics (NasdaqGS:TXG) announced new collaborations with Brigham & Women's Hospital, Dana-Farber Cancer Institute, and the Cancer Research Institute to apply its single-cell and spatial technologies to autoimmune disease and immuno-oncology research.
• The company also launched a multi-year initiative to establish a CLIA-certified laboratory aimed at future clinical applications of its platforms.

For investors watching 10x Genomics, the news comes with the stock at $23.19 and a mixed return profile. Shares are up 9.4% over the past week, 40.5% over the past month, 39.5% year to date, and 55.6% over the past year, while the 3 year and 5 year returns show declines of 51.7% and 86.6% respectively.

These collaborations and the CLIA lab plan place 10x Genomics more directly in translational medicine, cancer diagnostics, and immuno-oncology, areas closely watched by the market. Investors may focus on how effectively the company turns these research relationships and infrastructure plans into clinically oriented offerings over time.

Stay updated on the most important news stories for 10x Genomics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on 10x Genomics.

Quick Assessment

• ❌ Price vs Analyst Target: At $23.19, the share price sits above the US$18.23 analyst target range midpoint and above the US$22.00 high target.
• ❌ Simply Wall St Valuation: Valuation status is currently unknown, so you do not have a clear under or overvaluation signal to lean on.
• ✅ Recent Momentum: The stock has returned about 40.5% over the last 30 days, which is strong short term momentum.

Check out Simply Wall St's in depth valuation analysis for 10x Genomics.

Key Considerations

• 📊 The new research collaborations and CLIA lab plan move 10x Genomics further toward potential clinical and immuno oncology use cases, which many investors watch closely.
• 📊 It may be useful to monitor how CLIA lab build out costs, revenue at US$641.8m, and continued losses of US$76.3m change alongside any new partnership related revenue.
• ⚠️ A key risk flag is that earnings are forecast to decline by an average of 1.2% per year over the next 3 years while the business is still loss making.

Dig Deeper

For the full picture including more risks and rewards, check out the complete 10x Genomics analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.